Avid Bioservices has reported strong contract manufacturing revenues for its Q2 and is confident a planned third facility will not leave the firm with too much capacity.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
CRO Parexel’s staffing numbers took center stage during its earnings call Thursday as the company re-iterated plans to lay off as many as 850 employees – mostly in higher-cost countries -- to increase its margins.
Unilife has invested in manufacturing capacity for its drug delivery devices ahead of schedule to support the accelerated commercial launch date of its customers' products.
Canadian CMO Patheon’s second quarter revenues increased almost 40 percent as the company’s commercial manufacturing services revenues saw a similarly high rise over the same period from last year.
With a more than 27 percent increase in revenue for Q3 of FY 2013 over the same quarter last year, CRO Parexel has raised its guidance for both the fiscal and calendar year.
Parexel may have raised its forecast for fiscal 2013 after reporting a 26% hike in second quarter revenues this week, but analysts still have concerns about its spending.
Epistem says its focus on epithelial stem cell services and growth of its CRO and biomarker businesses helped it to stave off the downturn and post a strong set of financials of the fiscal year ended June 30.
With the next round of financial results coming up Outsourcing-Pharma takes a look at the growth of seven CROs over the past three years and how the downturn has impacted on them.
Contract pharmaceutical manufacturer Patheon is to buy Puerto Rican
rival Mova Pharmaceuticals in a transaction that could be valued as
high as $350 million in cash, stock and assumed debt.
For the second time this year, Germany's LION bioscience has
dropped its full-year sales targets after reporting a slump in
interim sales to €7.5 million.
